Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06897930 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
A Phase 1 study of Lupus Erythematosus, Systemic, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
- 16
- Study locations
NCT06897930: Recruiting Phase 1 study of Lupus Erythematosus, Systemic, sponsored by AstraZeneca.
NCT06897930 is a Phase 1 study of Lupus Erythematosus, Systemic that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 150 participants, below the 198-participant average among 29 other Lupus Erythematosus, Systemic trials with a reported enrollment target (24% lower). The trial reports 16 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06897930, a Phase 1 study of Lupus Erythematosus, Systemic, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
- 16
- Study locations
Study Summary
This is a Phase 1b/2, single-arm, open-label, multi-center, clinical study of AZD0120, a CD19/BCMA dual CAR T cell therapy, to evaluate the safety, tolerability, and efficacy in adult participants with refractory Systemic Lupus Erythematosus.
Primary Outcome
The incidence and severity of adverse events (AEs)
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- BIOLOGICAL AZD0120
Study Locations (16)
California
- Research Site - San Francisco
- Research Site - Stanford
New York
- Research Site - New York
- Research Site - Syracuse
North Carolina
- Research Site - Chapel Hill
- Research Site - Charlotte
Washington
- Research Site - Seattle
- Research Site - Seattle
Other
- Research Site - Darlinghurst
- Research Site - Melbourne
Florida
- Research Site - Tampa
Georgia
- Research Site - Atlanta
Maryland
- Research Site - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-04-21 |
| Est. Completion | 2029-05-01 |
| Phase | Phase 1 |
What NCT06897930 shows while recruiting
NCT06897930 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 198-participant average among 29 other Lupus Erythematosus, Systemic trials with a reported enrollment target (24% lower).
The record links to 1 condition, with Lupus Erythematosus, Systemic appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT06897930 lists 16 locations in 11 states (California, New York, North Carolina).
Frequently Asked Questions
What is clinical trial NCT06897930 about?
NCT06897930 is a clinical study titled "A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE". This is a Phase 1b/2, single-arm, open-label, multi-center, clinical study of AZD0120, a CD19/BCMA dual CAR T cell therapy, to evaluate the safety, tolerability, and efficacy in adult participants with refractory Systemic Lupus Erythematosus.
What is the current status of trial NCT06897930?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2025-04-21. Estimated completion is 2029-05-01.
What conditions does trial NCT06897930 study?
This clinical trial studies the following conditions: Lupus Erythematosus, Systemic.
What interventions are being tested in trial NCT06897930?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), AZD0120 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06897930?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06897930 being conducted?
This trial has 16 study locations across California, Florida, Georgia, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lupus Erythematosus, Systemic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06897930's enrollment target sits among peer trials
150 17th of 29 higher than 13 of 29 other Lupus Erythematosus, Systemic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lupus Erythematosus, Systemic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
RECRUITING · Phase 1
-
Anti-CD20 in Systemic Lupus Erythematosus
COMPLETED · Phase 1
-
Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis
COMPLETED · Phase 1
-
Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus
COMPLETED · Phase 1
-
Phase Ib Study of SC Milatuzumab in SLE
COMPLETED · Phase 1
-
Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE (ReLATE)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI